← Volver a la portada
Américas · Mercados regionales · BNN Bloomberg

Early test results for U.S. drug ‘one of the biggest breakthroughs’ for cancer, says Canadian oncologist

Publicado por BNN Bloomberg · Canadá hace 1 h
Pancreatic cancer doctor A doctor tends to patients in his office in Illinois on Oct. 30, 2012. (Jeff Roberson / AP)
Pancreatic cancer doctor A doctor tends to patients in his office in Illinois on Oct. 30, 2012. (Jeff Roberson / AP) · BNN Bloomberg

Resumen detallado

An experimental U.S. drug that saw positive results in patients during early tests is a major ‘breakthrough’ for cancer patients, Canadian doctors say.

An experimental U.S. drug that saw positive results in patients during early tests is a major “breakthrough” for cancer patients, Canadian doctors say.

A U.S. drugmaker reported Friday that its pill, ERAS-0015, reduced tumours in nearly half of the patients with advanced pancreatic and lung cancers in an early-stage clinical trial.

Erasca, based in San Diego, Calif., said 44 per cent of 25 patients with pancreatic cancer saw tumours shrink substantially after they took a 32 mg daily dose of the drug.

Additionally, 69 per cent of patients with the two most common genetic variations of pancreatic cancer experienced positive results after taking the drug.

For lung cancer, tumours diminished in three of five patients (60 per cent) who had previously received immunotherapy and chemotherapy.

Erasca said it would begin late-stage clinical trials to test the drug and another experimental treatment called ERAS-4001 in 2027.

Dr. Jennifer Knox, staff medical oncologist at the University Health Network’s Princess Margaret Cancer Centre in Toronto, will be supervising patients when the clinical trial of the new drug comes to Canada next year as part of the global tests.

“It’s the biggest breakthrough for pancreas cancer probably ever,” Knox said in a phone interview with CTVNews.ca on Friday. “It’s one of the biggest breakthroughs for cancer in general in recent years.”

However, the early stage of the Erasca trial only involved a small number of patients, which Knox said is “typical” at that phase. She expects a large number of people to participate in the upcoming clinical trial in Canada, she added.

Inicio del artículo, extracto de BNN Bloomberg. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en BNN Bloomberg Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.bnnbloomberg.ca)

También te puede interesar